Additional Diagnostic Tests: Results of flow cytometric testing indicate an abnormal population in the R2 blast gate. These blasts, which accounted for 40% of the nucleated cells studied, tested positive for B-cell markers CD19 and CD22 and biphenotypic for CD20. The blast cells also tested positive for CD10 and terminal deoxynucleotidyl transferase (TdT).
1. The patient's most striking clinical findings on initial complete blood count (CBC) testing were marked leukocytosis and marked thrombocytopenia. The patient's chemistry findings include increased glucose and lactate dehydrogenase (LDH) levels, as well as decreased blood urea nitrogen (BUN), creatinine, and osmolality (Table 1) .
Bumps on the Neck and Groin of a 2-Year-Old Male

Erikakelly Strand, BS*
Clinical History
Patient: 2-year-old white male.
Chief Complaint: Bumps on neck and groin.
History of Present Illness:
A 2-year-old boy arrived at the emergency department with a 1-to 2-week history of bumps on his neck and groin. He had been referred to the emergency department by his primary care physician (PCP) when the results of an in-office fingerstick blood test revealed a high white blood cell (WBC) count and a low platelet count. The parents of the patient say that he had had bilateral knee pain a few days previously, which had resolved spontaneously, and had had a cough for the past week. The parents mentioned that when their son had started coughing one week prior, they had contacted the PCP and had mentioned the bumps on his neck and his cough. The physician diagnosed the boy as having lymphadenopathy attributed to a viral illness.
Medical and Family History:
As of this writing, the patient's immunizations are up to date. He experiences seasonal allergies, with symptoms that include itchy eyes and runny nose. His recurrent ear infections have been resolved by pressure-equalization tubes and adenoidectomy.
The patient's maternal grandmother and maternal uncle have long QT syndrome. His paternal great-grandfather has a low platelet count (specificity not given). The patient lives with his parents; as of this writing, his mother is currently at 31 weeks' gestation, originally with triplets but currently with twins (one fetus recently died in utero).
Physical Examination: During examination to determine the extent of symptoms, abnormalities were found in the respiratory, lymphatic, and musculoskeletal systems. The patient was observed to cough and have leg and knee pain; he also had swollen lymph glands.
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The abnormal elevated WBC count caused an automatic manual review of the patient's blood smear. Elevated LDH levels are an indicator for acute or chronic tissue damage and can be used to monitor the progression of certain cancers. 1 The decreased BUN and creatinine levels indicated that further testing was required.
2. The results of the patient's peripheral blood smear (PBS) revealed marked thrombocytopenia combined with leukocytosis. The differential showed a marked decrease in neutrophils, lymphocytes, and monocytes. Along with the decreased relative WBC count, polychromasia and schistocytes were present. The most striking characteristic of the patient's PBS is a predominance (ie, 74%) of blasts (Image 1, part A and Table 2 ). The high blast percentage falsely elevated the WBC count in the initial CBC. The most striking characteristic of the bone marrow (BM) differential was marked hypercellularity, with a blast result of 94% (Image 1, part B and Table 2 ). 
Image 1
Patient's laboratory results via Wright-Giemsa stained peripheral blood smear (original magnification, ×40). A, image illustrating leukocytosis, thrombocytopenia, and lymphoblasts. B, Bone marrow image illustrating hypercellularity and increased proliferation of lyphoblasts.
A B Flow cytometry testing indicated that the side scatter plot versus marker CD45, a common leukocyte antigen, showed an abnormal population of immature cells in the R2 blast gate, which accounted for 40% of the nucleated cells studied (Image 2). These blast cells were then further differentiated; it was noted that the B cells were positive for markers CD19, CD22, CD10, and TdT. These cells also tested positive for human leukocyte antigen serotype DR (HLA-DR) (Image 3). The test results indicate that the patient's acute leukemia was subtyped to pre-B-cell acute lymphoblastic leukemia (Pre-B ALL). A fluorescence in situ hybridization (FISH) panel was performed; the results indicated no TEL/AML1, BCR/ ABL, or MLL gene arrangement. It was also noted that no trisomies were observed on chromosomes 4, 10, or 17.
ALL is a malignant neoplasm of precursor B-or T-cells that affects mostly children, with a peak incidence occurring in individuals of approximately 2 to 4 years of age. B-cell ALL (B-ALL) accounts for approximately 80% to 85% of all newly diagnosed ALL cases every year. 3, 4 The worldwide incidence is estimated at 1 to 4.75 per 100,000 people per year. 5 It has been reported that males are predominantly affected by B-ALL. 4, 5 Patients often experience fever, bleeding, fatigue, and severe bone pain. Bone pain can be Patients may have nodal and extranodal involvement. 3, 5 Laboratory findings include a form of cytopenia, such as anemia or thrombocytopenia. The overall leukocyte count can be increased, decreased, or normal, with a median count of approximately 10 to 12 × 10 9 /L ( Table 3) .
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However, the presence of a high percentage of circulating blasts can often falsely elevate the total leukocyte count. 3 Blast cells are usually medium sized with scant cytoplasm, moderately condensed to dispersed chromatin, and nucleoli that may not be readily discernible. 5 Flow cytometry testing can help differentiate among the various forms of B-ALL by identifying the CD markers that exist on the leukocytes. For a patient to be diagnosed with B-ALL, most of the leukocytes must express specific markers, including CD19 and/or CD20, which are primarily found on cells committed to the B-cell maturation process. 4, 5 Precursor-B lymphoblasts often present are TdT + and HLA-DR + . Moreover, the expression of CD10, the common ALL antigen (CALLA), differentiates intermediate pre-B from pro-B-ALL ( Table 4) . 4. It is currently believed that ALL arises from mutations at critical steps in the cell-maturation process. 4 It is also believed that environmental factors contribute to ALL; however, this has not been fully elucidated. 6 These mutations have been detected in neonatal samples long before the onset of leukemia in approximately 90% of childhood ALL. 5, 7 WHO currently classifies B-ALL into 5 categories according to which genetic abnormality is found (Table 5) .However, these genotypes are comprised of only 60% of pre-B ALL; the remaining 40% are unknown or rare. 8 The Philadelphia chromosome occurs in only about 2-5% of ALL cases and is one of the rarest causes of leukemia. 4, 9 Clinically, patients with this chromosome tend to be older and have a higher leukocyte count at the time of diagnosis. 9 It is important to diagnose this condition via FISH studies due to its poor prognosis. 4 Another rare genetic abnormality linked to pre-B ALL is mixed-lineage leukemia gene (MLL) rearranged, which accounts for approximately 6% of all cases. 3, 4 Currently, more than 60 genes are in this category. However, a study 4 has shown that certain gene rearrangements have been observed to occur in approximately 60% of MLL-related leukemias. These leukemias tend to involve high WBC counts and often show central nervous system (CNS) involvement. 4 Both leukemias are also associated with poor prognosis. The most common genetic abnormality observed is t(12;21) (p12;q22), which produces the TEL-AML1 fusion gene. The expression of this gene has been associated with favorable prognosis, with an event-free survival rate of 90%. [3] [4] [5] The results of FISH studies indicated that the patient did not express any of the genetic abnormalities commonly used to categorize acute leukemia. However, a current study 8 has shown that more abnormalities have been observed to be recurrent and may be added to the current FISH panel for diagnostic testing in the future. 8 Further molecular studies are needed to properly assess whether the patient harbors any abnormalities.
5. Children diagnosed with ALL have approximately a 95% chance of remission if treated with combination chemotherapy. Of these treated patients, approximately 80% are disease-free 5 years after diagnosis. 4, 5 Treatments today include systemic chemotherapy and CNS therapy. 4 A number of new treatments are available to newly diagnosed patients through Children's Oncology Group (COG) studies, which follow strict protocols and are offered to newly diagnosed patients who have not responded to treatment, have relapsed, or are in the maintenance phase. The specific therapy recommended for patients is dependent on the risk group to which the patient belongs, according to the patient's genetic features ( Table 5) . Other factors, such as age and leukocyte count, are also taken into consideration. 10 Chemotherapy for ALL is divided into 3 stages. The first stage, induction therapy, is administered to eradicate the leukemic blast population. 3 The drugs administered during this period are usually a glucocorticoid, vincristine, and asparaginase. 10 The second stage, the CNS prophylactic stage, is administered because the most common site of relapse is the CNS 3 ; the drugs in this stage are administered at higher doses. Periodically, high-dose methotrexate (an antimetabolite) and 6-mercaptopurine (an immunosuppressant) can be used. 10 The final stage of treatment, maintenance chemotherapy, is designed to eradicate any remaining leukemic cells and to prolong remission. 3 To be cured, patients with pre-B ALL require a 2-to 2½-year course of therapeutic agents. It has been observed that males need to be treated longer than females because relapse can occur in the testes. 10 
